Citadel Advisors
XLO icon

Citadel Advisors’s Xilio Therapeutics XLO Stock Holding History

Citadel Advisors’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Buy
+25,950
New +$217K ﹤0.01% 11566
2026
Q1 		– Sell
-31,158
Closed -$279K – 14389
2025
Q4 		$279K Buy
+31,158
New +$327K ﹤0.01% 10301
2025
Q1 		– Sell
-2,880
Closed -$38.5K – 15715
2024
Q4 		$38.5K Buy
+2,880
New +$39.6K ﹤0.01% 12646
2024
Q1 		– Sell
-3,673
Closed -$28.3K – 15536
2023
Q4 		$28.3K Buy
+3,673
New +$72.6K ﹤0.01% 12311
2023
Q3 		– Sell
-939
Closed -$34.5K – 15238
2023
Q2 		$34.5K Sell
939
-4,178
-82% -$178K ﹤0.01% 12217
2023
Q1 		$228K Buy
+5,117
New +$225K ﹤0.01% 9945

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors's XLO Position: Q2 2026 in Review

Citadel Advisors opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 25,950 shares worth $249K. The stake represents ﹤0.01% of the portfolio and ranks #11566 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in XLO as recently as Q4 2025.

Citadel Advisors first reported a position in XLO in Q1 2023 and has held it in 6 quarters since. The position peaked at $279K in Q4 2025. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Citadel Advisors held 25,950 shares of Xilio Therapeutics worth $249K as of Q2 2026.
  • Xilio Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Xilio Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11566 holding.
  • Citadel Advisors first reported a position in Xilio Therapeutics in Q1 2023 and has held it in 6 quarters since.
  • Citadel Advisors's Xilio Therapeutics position peaked at $279K in Q4 2025.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.